Biohaven (BHVN) Projected to Post Earnings on Thursday

Biohaven (NYSE:BHVN) is anticipated to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect Biohaven to post earnings of ($1.64) per share and revenue of $1.25 million for the quarter.

Biohaven (NYSE:BHVN) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.29). On average, analysts expect Biohaven to post $-9 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Biohaven Trading Down 1.1 %

Shares of BHVN opened at $22.59 on Tuesday. Biohaven has a twelve month low of $15.79 and a twelve month high of $55.70. The firm has a market capitalization of $2.31 billion, a P/E ratio of -2.42 and a beta of 1.18. The stock’s fifty day simple moving average is $24.61 and its 200 day simple moving average is $36.15.

Insider Buying and Selling at Biohaven

In related news, Director John W. Childs acquired 32,700 shares of the firm’s stock in a transaction on Tuesday, March 4th. The stock was bought at an average cost of $30.47 per share, with a total value of $996,369.00. Following the acquisition, the director now directly owns 2,320,571 shares in the company, valued at approximately $70,707,798.37. The trade was a 1.43 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 16.00% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BHVN. Morgan Stanley decreased their target price on Biohaven from $69.00 to $63.00 and set an “overweight” rating for the company in a report on Friday, March 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 price objective on shares of Biohaven in a research report on Tuesday, March 4th. Robert W. Baird reduced their target price on shares of Biohaven from $60.00 to $57.00 and set an “outperform” rating on the stock in a report on Monday, April 28th. William Blair raised shares of Biohaven to a “strong-buy” rating in a research report on Thursday, April 24th. Finally, HC Wainwright reissued a “buy” rating and issued a $54.00 price objective on shares of Biohaven in a research report on Tuesday, March 4th. Fourteen investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $62.54.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.